Cargando…

Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study

BACKGROUND: Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed. METHODS: From a community-based sample of 4,409 individuals residin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayav, Carole, Beuscart, Jean-Baptiste, Briançon, Serge, Duhamel, Alain, Frimat, Luc, Kessler, Michèle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111196/
https://www.ncbi.nlm.nih.gov/pubmed/27846810
http://dx.doi.org/10.1186/s12882-016-0379-3
_version_ 1782467821366673408
author Ayav, Carole
Beuscart, Jean-Baptiste
Briançon, Serge
Duhamel, Alain
Frimat, Luc
Kessler, Michèle
author_facet Ayav, Carole
Beuscart, Jean-Baptiste
Briançon, Serge
Duhamel, Alain
Frimat, Luc
Kessler, Michèle
author_sort Ayav, Carole
collection PubMed
description BACKGROUND: Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed. METHODS: From a community-based sample of 4,409 individuals residing in a well-defined geographical area, we determined the number of patients having a first serum creatinine value ≥1.7 mg/dL and present for at least 3 months that allowed us to calculate an annual incidence rate of CKD (stages 3 to 5). CKD (stages 3 to 5) was defined by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2). We also described the primary care, outcomes and risk factors associated with outcomes using competing risks analyses for these CKD patients. RESULTS: A total of 631 incident CKD patients (stages 3 to 5) were followed-up until the occurrence of death and dialysis initiation for more than 3 years. The annual incidence rate of CKD (stages 3 to 5) was estimated at 977.7 per million inhabitants. Analyses were performed on 514 patients with available medical data. During the study, 155 patients (30.2 %) were referred to a nephrologist, 193 (37.5 %) died and 58 (11.3 %) reached end-stage renal disease and initiated dialysis. A total of 139 patients (27.6 %) had a fast decline of their renal function, 92 (18.3 %) a moderate decline and the 272 remaining patients had a physiological decline (21.1 %) or a small improvement of their renal function (33.0 %). Predictors of death found in both Cox and Fine-Gray multivariable regression models included age at diagnosis, anemia, active neoplasia and chronic heart failure, but not a low glomerular filtration rate (GFR). Age at diagnosis, anemia and a low GFR were independently associated with dialysis initiation in Cox model, but anemia was not found to be a risk factor for dialysis initiation in Fine-Gray model. CONCLUSIONS: This large cohort study provided useful epidemiological data on incident CKD (stages 3 to 5) and stressed the need to improve the hands-on implementation of clinical practice guidelines for the evaluation and the management of CKD in primary care.
format Online
Article
Text
id pubmed-5111196
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51111962016-11-25 Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study Ayav, Carole Beuscart, Jean-Baptiste Briançon, Serge Duhamel, Alain Frimat, Luc Kessler, Michèle BMC Nephrol Research Article BACKGROUND: Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed. METHODS: From a community-based sample of 4,409 individuals residing in a well-defined geographical area, we determined the number of patients having a first serum creatinine value ≥1.7 mg/dL and present for at least 3 months that allowed us to calculate an annual incidence rate of CKD (stages 3 to 5). CKD (stages 3 to 5) was defined by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2). We also described the primary care, outcomes and risk factors associated with outcomes using competing risks analyses for these CKD patients. RESULTS: A total of 631 incident CKD patients (stages 3 to 5) were followed-up until the occurrence of death and dialysis initiation for more than 3 years. The annual incidence rate of CKD (stages 3 to 5) was estimated at 977.7 per million inhabitants. Analyses were performed on 514 patients with available medical data. During the study, 155 patients (30.2 %) were referred to a nephrologist, 193 (37.5 %) died and 58 (11.3 %) reached end-stage renal disease and initiated dialysis. A total of 139 patients (27.6 %) had a fast decline of their renal function, 92 (18.3 %) a moderate decline and the 272 remaining patients had a physiological decline (21.1 %) or a small improvement of their renal function (33.0 %). Predictors of death found in both Cox and Fine-Gray multivariable regression models included age at diagnosis, anemia, active neoplasia and chronic heart failure, but not a low glomerular filtration rate (GFR). Age at diagnosis, anemia and a low GFR were independently associated with dialysis initiation in Cox model, but anemia was not found to be a risk factor for dialysis initiation in Fine-Gray model. CONCLUSIONS: This large cohort study provided useful epidemiological data on incident CKD (stages 3 to 5) and stressed the need to improve the hands-on implementation of clinical practice guidelines for the evaluation and the management of CKD in primary care. BioMed Central 2016-11-15 /pmc/articles/PMC5111196/ /pubmed/27846810 http://dx.doi.org/10.1186/s12882-016-0379-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ayav, Carole
Beuscart, Jean-Baptiste
Briançon, Serge
Duhamel, Alain
Frimat, Luc
Kessler, Michèle
Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study
title Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study
title_full Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study
title_fullStr Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study
title_full_unstemmed Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study
title_short Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study
title_sort competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the epiran community-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111196/
https://www.ncbi.nlm.nih.gov/pubmed/27846810
http://dx.doi.org/10.1186/s12882-016-0379-3
work_keys_str_mv AT ayavcarole competingriskofdeathandendstagerenaldiseaseinincidentchronickidneydiseasestages3to5theepirancommunitybasedstudy
AT beuscartjeanbaptiste competingriskofdeathandendstagerenaldiseaseinincidentchronickidneydiseasestages3to5theepirancommunitybasedstudy
AT brianconserge competingriskofdeathandendstagerenaldiseaseinincidentchronickidneydiseasestages3to5theepirancommunitybasedstudy
AT duhamelalain competingriskofdeathandendstagerenaldiseaseinincidentchronickidneydiseasestages3to5theepirancommunitybasedstudy
AT frimatluc competingriskofdeathandendstagerenaldiseaseinincidentchronickidneydiseasestages3to5theepirancommunitybasedstudy
AT kesslermichele competingriskofdeathandendstagerenaldiseaseinincidentchronickidneydiseasestages3to5theepirancommunitybasedstudy